Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 59

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 59
---
ultaneously
with the closing of the Initial Public Offering, the Company consummated the sale of 400,000 units (the “Private Placement Units”)
at a price of $10.00 per Private Placement Unit in a private placement to Drugs Made In America Acquisition LLC (the “Sponsor”),
for $4,000,000, of which $1,100,000 was not received and included as share subscription receivable. Since the Initial Public Offering
until September 30, 2025, the Sponsor has paid $491,178 in expenses on behalf of the Company (including $81,000 related to
the administrative support agreement) affecting the share subscription receivable on the unaudited balance sheet to $608,822.
Simultaneously with the sale of the over-allotment option Units on February 18, 2025, the Sponsor purchased an additional 30,000 Private
Placement Units at a purchase price of $10.00 per Private Placement Unit, generating additional gross proceeds of $300,000.

The
Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering
and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating
a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company
must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal
to at least 80% of the net assets held in the Trust Account (as defined below) (excluding any deferred underwriting fees and taxes payable
on the interest earned on the Trust Account) at the time of the agreement to enter into the initial business combination. The Company
will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities
of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as
an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

5

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Following
the closing of the Initial Public Offering on January 29, 2025 and the over-allotment option closing